Mumbai, February 27, 2021.
ICPA Health Products Ltd (ICPA), a leading pharmaceutical company and pioneers in the oral-health segment has launched ICPAMOX – CV 625 meant to treat odontogenic infections. The product is an antibiotic with a broad-spectrum activity against the commonly occurring bacterial pathogens in the oral cavity and other parts of the body. An antibiotic indicated in multiple conditions, ICPAMOX – CV 625 is recommended for use along with dental treatments like root canal, tooth extractions and various oral surgeries to reduce post-operative infection. The product composition is Amoxycillin 500mg + Clavulanic acid 125mg and is approved by the DCGI.
“The launch of ICPAMOX – CV 625 is a testament to our focus in the oral health care segment. ICPAMOX – CV 625 marks our foray into antibiotics and we plan to introduce more products in the segment. The product is extremely effective for treating odontogenic infections in patients undergoing various types of dental treatments,” says Ms Abha Damani, Director, ICPA.
ICPA are the manufacturers of trusted brands like Thermoseal and Hexidine in the oral health-care segment and are also present in the dermatology, haemorrhoids and ENT segments. It also has products in the FMCG segment with brands in perfumes, sanitizers, hand-washes, disinfectants and soaps, among others.
A box of ICPAMOX – CV 625 is available at an MRP of Rs.189/- and contains 10 tablets.